A Correlative Science Study for ECOG E5194
- To validate the prognostic utility of the Oncotype DX Recurrence Score® assay in tissue
samples from patients with ductal breast carcinoma in situ enrolled on clinical trial
OUTLINE: RNA extracted from archived tissue samples are analyzed for gene expression profile
by Oncotype DX Recurrence Score® assay (a reverse transcriptase-PCR-based assay).
Ipsilateral local failure (first event of invasive or ductal carcinoma in situ [DCIS] recurrence)
Lawrence J. Solin, MD, FACR
Abramson Cancer Center of the University of Pennsylvania